

Automated Amplicon Library Preparation

with MagicPrep™ NGS.

Application Note

MagicPrep NGS.

TECAN.

AUTOMATED LIBRARY PREP THAT JUST WORKS



INTRODUCTION

Automated library prep for amplicon-based workflows

Routine manual preparation of amplicon-based libraries can be burdensome to personnel, requiring at least 5 hours of assay time and allots only 0.5 hours of uninterrupted walkaway time. MagicPrep™ NGS is an ideal solution for saving time by automating the generation of amplicon-based libraries.

MagicPrep NGS offers a fully automated workflow to generate high quality amplicon-based libraries. The workflow may be used with Revelo™ DNA-Seq Enz for MagicPrep NGS for large amplicon sizes (> 300 bp) or with Revelo™ DNA-Seq Mech for MagicPrep NGS for smaller amplicon sizes (< 300 bp). Running the instrument is a 1-step process allowing for 5.5 hours of uninterrupted walkaway time (**Figure 1**). This time savings of 9x over standard manual workflows provide lab scientists ample time to perform other tasks, including preparing the next set of samples.

CASE STUDY: MAGICPREP NGS WITH SARS-COV-2 AMPLICONS

Amplicon libraries generated from patient nasal swab

MagicPrep NGS was used to generate amplicon-based DNA libraries using primers from the QIAseq® SARS-CoV-2 Primer Panel with the goal of sequencing across the SARS-CoV-2 genome and subsequently identifying the SARS-CoV-2 strain for a given sample. Total RNA was extracted from a nasal swab sample from a SARS-CoV-2-positive patient and titrated down to Ct18, Ct21, and Ct24. Amplicons were generated from the titrated samples using the QIAseq SARS-CoV-2 Primer Panel RT-PCR protocol. PCR amplicons from the 3 samples were loaded with 2 different input amounts (25 ng and 100 ng) in duplicates for a total of 12 libraries. Once loaded into MagicPrep NGS, the Revelo DNA-Seq Enz for MagicPrep NGS kit was used in order to fragment the 400 bp amplicons down to 200 bp (**Figure 2**). The resulting libraries were sequenced on the MiniSeq System at 2x75 bp read length.

Library quality enabled SARS-CoV-2 strain detection with 1M read pairs

Sequencing data from each library were subsampled down to 1 million read pairs and aligned to the SARS-CoV-2 reference genome (MN908947.3). The alignment rate of the reads was over 99 % across all samples (**Figure 3**). The coverage pattern was, expectedly, uniform across most of the reference genome¹ (**Figure 4**). On average, the uniformity of coverage across all samples was approximately 89 % (**Figure 5**). The fidelity of the generated data allows for the identification of the SARS-CoV-2 strain across all samples (Omicron variant BA.1). The success of the SARS-CoV-2 amplicon library prep and sequencing analysis underscores the application of MagicPrep NGS for amplicon-based library preparation.



5.5 hours uninterrupted walkaway time




Figure 1: MagicPrep NGS automates the entire library prep workflow from DNA fragmentation through amplification, and purification to provide sequencing-ready libraries in 5.5 hours.

Insert Size Distribution of Amplicon Libraries




Figure 2: The insert size of the library after using the Revelo DNA-Seq Enz for MagicPrep NGS has a normal distribution averaging 200 bp.






Figure 3: The alignment rate was over 99 % across all samples (a and b correspond to technical replicates) even at 25 ng input amounts, indicating minimal read artifact and contamination with the MagicPrep NGS workflow.




Figure 4: This is a representative coverage pattern as was observed across all samples (Ct18 sample shown). The level of coverage and uniformity was sufficient to determine that this sample is Omicron variant BA.1.




Figure 5: Coverage uniformity is consistent between the two input amounts for MagicPrep NGS, averaging ~89 %.

SUMMARY

The MagicPrep NGS platform is an automated solution for NGS library prep. The MagicPrep NGS alleviates the labor burden needed for manual amplicon-based library prep by providing 5.5 hours of uninterrupted walkaway time. The workflow can be used with shorter amplicons (< 300 bp) using Revelo DNA-Seq Mech for MagicPrep NGS and longer amplicons (> 300 bp) using Revelo DNA-Seq Enz for MagicPrep NGS.

This case study with SARS-CoV-2 amplicons highlights MagicPrep NGS' ability to generate amplicon-based libraries with high alignment rate and uniform coverage across all samples, allowing for the identification of the SARS-CoV-2 Omicron variant BA.1 for each sample.



REFERENCES

- 1) Lambisia AW, *et al.* Optimization of the SARS-CoV-2 ARTIC Network V4 Primers and Whole Genome Sequencing Protocol. *Front Med (Lausanne)*, 2022, **9**:836728.
<https://doi.org/10.3389/fmed.2022.836728>

For Research Use Only. Not for use in diagnostic procedures.

.....
Australia +61 3 9647 4100 **Austria** +43 62 46 89 330 **Belgium** +32 15 42 13 19 **China** +86 21 220 63 206 **France** +33 4 72 76 04 80 **Germany** +49 79 51 94 170
Italy +39 02 92 44 790 **Japan** +81 44 556 73 11 **Netherlands** +31 18 34 48 17 4 **Nordic** +46 8 750 39 40 **Singapore** +65 644 41 886 **Spain** +34 93 595 25 31
Switzerland +41 44 922 89 22 **UK** +44 118 9300 300 **USA** +1 919 361 5200 **Other countries** +41 44 922 81 11

Tecan Group Ltd. makes every effort to include accurate and up-to-date information within this publication; however, it is possible that omissions or errors might have occurred. Tecan Group Ltd. cannot, therefore, make any representations or warranties, expressed or implied, as to the accuracy or completeness of the information provided in this publication. Changes in this publication can be made at any time without notice. For technical details and detailed procedures of the specifications provided in this document please contact your Tecan representative. This brochure may contain reference to applications and products which are not available in all markets. Please check with your local sales representative.

Tecan, MagicPrep and Revelo are registered trademarks and trademarks of Tecan Group Ltd., Männedorf, Switzerland or of Tecan Genomics, Inc., Redwood City, USA.

QIAseq is a registered trademark of the Qiagen Group, Venlo, The Netherlands.

© 2023 Tecan Genomics, Inc., all rights reserved. For disclaimer and trademarks please visit www.tecan.com

www.tecan.com

